Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Firmonertinib - Allist Pharmaceuticals/ArriVent Biopharma

Next Previous
Drug Profile

Firmonertinib - Allist Pharmaceuticals/ArriVent Biopharma

Alternative Names: Alflutinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; AST-2818; Furmonertinib; Furmonertinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; Iflutinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma; Ivesa; Vometinib mesylate - Allist Pharmaceuticals/ArriVent Biopharma

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allist Pharmaceuticals
  • Developer Allist Pharmaceuticals; ArriVent Biopharma
  • Class Amides; Antineoplastics; Diamines; Fluorinated hydrocarbons; Indoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 28 May 2025 Phase-III clinical trials in Non-small cell lung cancer (Neoadjuvant therapy) in China (PO) (NCT07010419)
  • 31 Mar 2025 ArriVent BioPharma completes enrolment in its phase III trial for Non small cell lung cancer (Late stage disease, Metastatic disease, First line therapy) in USA, Australia, China, France, Italy, Japan, South Korea, Malaysia, the Netherlands, Phillipines, Singapore, Spain, Taiwan, Thailand, Brazil, the United Kingdom, Canada, Mexico and Israel
  • 19 Nov 2024 Allist Pharmaceuticals initiates enrolment in a phase-III trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO, Tablet) (NCT06956001)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top